

**Original Research Article** 

# Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness

# Gustavs Latkovskis<sup>*a,b,c,\**</sup>, Inga Urtane<sup>*d*</sup>, Agnese Knipse<sup>*a*</sup>, Raitis Peculis<sup>*e*</sup>, Inese Cakstina<sup>*f*</sup>, Janis Klovins<sup>*e*</sup>, Andrejs Erglis<sup>*a,b,c*</sup>

<sup>a</sup> Latvian Centre of Cardiology, Paul Stradins Clinical University Hospital, Riga, Latvia

<sup>b</sup>Latvian Research Institute of Cardiology, Riga, Latvia

<sup>c</sup> Faculty of Medicine, University of Latvia, Riga, Latvia

<sup>d</sup> Faculty of Pharmacy, Riga Stradins University, Riga, Latvia

<sup>e</sup>Latvian Biomedical Research and Study Centre, Riga, Latvia

<sup>f</sup>Cell Transplantation Centre, Paul Stradins Clinical University Hospital, Riga, Latvia

# ARTICLE INFO

Article history: Available online 6 June 2014

Keywords: Clopidogrel resistance VASP CYP2C19 ABCB1 CYP2C9

# ABSTRACT

Background and objective: Additional loading doses and higher maintenance doses (MDs) have been used to overcome hyporesponsiveness of clopidogrel. We aimed to investigate whether genetic polymorphisms of two cytochromes (CYP2C19 and CYP2C9) and ABCB1 modify effect of such dose-adjustment strategy.

Materials and methods: We enrolled 118 patients undergoing elective or acute percutaneous coronary intervention (PCI) with drug eluting stent (DES). Platelet reactivity index (PRI) was measured using the vasodilator-stimulated phosphoprotein (VASP) index and a cut-off value of  $\geq 60\%$  was defined as hyporesponsiveness. Polymorphism of two cytochromes (CYP2C19, CYP2C9) and gene ABCB1 were determined. In patients hyporesponsive to the initial LD the dose-adjustment was performed using up to 3 additional 600 mg LDs in order to achieve PRI <60\%, and both 150 mg and 75 mg MD were tested at the follow-up.

Results: Patients with at least one CYP2C19\*2 allele had higher baseline PRI after the initial LD (78.2  $\pm$  13.1 vs. 65.3  $\pm$  19.5, P = 0.005). The PRI reduction with additional LD was significantly smaller in carriers of the CYP2C19\*2 (25.2  $\pm$  15.6 vs. 35.5  $\pm$  16.8, P = 0.025) and similar trend was observed with subsequent additional LDs. Both MDs were less effective in presence of CYP2C19\*2. Target PRI was, however, more frequently achieved with higher MD even in presence of CYP2C19\*2 (in 70.6% vs. 23.5% of hyporesponders, P = 0.008). No such differences were observed for other polymorphisms.

\* Corresponding author at: Latvian Centre of Cardiology, Paul Stradins Clinical University Hospital, Pilsonu 13, 1002 Riga, Latvia. E-mail address: gustavs.latkovskis@gmail.com (G. Latkovskis).

Peer review under responsibility of Lithuanian University of Health Sciences.



http://dx.doi.org/10.1016/j.medici.2014.05.004

1010-660X/ © 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Conclusions: In patients hyporesponsive to a routine clopidogrel doses the potency of additional LD and higher MD of clopidogrel is compromised by presence of CYP2C19\*2 allele. The dose-adjustment strategy is not affected by ABCB1 C3435T or CYP2C9 genotypes. © 2014 Lithuanian University of Health Sciences. Production and hosting by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

# 1. Introduction

Dual antiplatelet therapy (DAPT) as a combination of aspirin and a P2Y<sub>12</sub>-receptor antagonist reduces thrombotic complications in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), and it is a recommended treatment in current clinical guidelines [1]. For the last decade as a standard DAPT was the combination of aspirin and clopidogrel until newer generation more effective P2Y<sub>12</sub>-receptor antagonists (prasugrel, ticagrelor) became available which provide more rapid, potent and reliable P2Y<sub>12</sub>-receptor inhibition [1–3]. Although prasugrel and ticagrelor reduced the risk of cardiovascular death, myocardial infarction or stroke compared to clopidogrel in patients with ACS, the concerns of higher bleeding risk coupled with an increase in costs remain important shortcomings with the newer agents [4,5]. These considerations have encouraged the further investigation in a search for more personalized approach in each individual patient.

The pharmacodynamic response to clopidogrel varies among patients and standard doses of clopidogrel achieve suboptimal platelet inhibition. Hence, the "high on-treatment platelet reactivity" (HTPR) or hyporesponsiveness has been described in up to 50% of patients [2,6]. Numerous individual studies as well as several meta-analyses have demonstrated that HTPR is strongly associated with cardiovascular death, myocardial infarction and stent thrombosis (ST) in patients undergoing PCI [7].

Routine or platelet function testing-guided administration of higher or repeated clopidogrel loading doses (LDs) and higher maintenance doses (MDs) have failed to overcome hyporesponsiveness in a significant proportion of patients and yielded unsatisfactory long-term clinical results [8–15]. Genetic variants of CYP2C19 and ABCB1 genes have been associated with hyporesponsiveness and cardiovascular events among patients on treatment with clopidogrel [16]. Variations of these genes affect the rate of metabolism of clopidogrel that is pro-drug, and production of the active metabolite [16,17]. There are limited data if and how these polymorphisms affect the efficacy of tailored additional LDs and MDs used in hyporesponsive patients [18].

We aimed to investigate whether genetic polymorphisms of CYP2C19, ABCB1 and CYP2C9 modify effect of (i) additional 600 mg LDs of clopidogrel and (ii) higher MD (150 mg vs. 75 mg) in order to overcome hyporesponsiveness.

# 2. Materials and methods

In a prospective single-center study we included patients undergoing PCI with a drug eluting stent (DES) who received LD

of clopidogrel according to the guidelines, namely, 300 mg or 600 mg for patients with scheduled or acute PCI, respectively [19-21]. The enrollment period was between September 2010 and December 2012. The following exclusion criteria were applied: expected noncompliance to therapy, congestive heart failure New York Heart Association functional class IV, bleeding or history of bleeding diathesis, platelet count  ${<}100\times10^{9}$  /L, oral anticoagulant therapy, chronic liver disease (cirrhosis, hepatitis) or serum bilirubin >2 mg/dL, hemorrhagic stroke or stroke of unspecified origin, malignancy or other concurrent severe illness with expected survival <1 year, contraindication to dual antiplatelet therapy as deemed by the treating physician. The protocol was approved by the local ethics committee and was according to the Declaration of Helsinki. Patients were included after two informed consents were obtained separately for each of two study components: treatment to clopidogrel and genetic investigation. Among initially included 118 patients only 94 patients fully adhered to the study design. One patient withdrew consent to the genetic analysis during the study therefore we report data on 93 patients. The remaining 24 patients were excluded during the study due to the following deviations from the protocol: incorrect use of clopidogrel doses (n = 12), treating physician changed clopidogrel to another antiplatelet drug (n = 8), patients refused a follow-up visit (n = 4). Minority of the patients (n = 18, 19.4%) underwent emergent or urgent PCI due to an acute coronary syndrome.

#### 2.1. Blood samples

Blood samples for VASP phosphorylation analyses were drawn by atraumatic venipuncture of the antecubital vein. The first sample was taken after the PCI with DES on the second day after the routine LD. The subsequent samples were taken between 12 and 24 h after each additional LD, and at least 3 h after the last MD at the follow-up. Blood was collected into a vacutainer containing 3.8% trisodium citrate and filled to capacity. The vacutainer was inverted 3–5 times for gentle mixing and taken to the laboratory.

# 2.2. Platelet reactivity measurements

The VASP phosphorylation analysis was performed within 24 h of blood collection by an experienced investigator using Platelet VASP kits (PLT VASP/P2Y12, Biocytex, Marseille, France) according to the manufacturer's instructions [22]. A citrated blood sample was incubated with prostaglandin  $E_1$  (PGE<sub>1</sub>) and ADP 10  $\mu$ mol/l for 10 min and fixed with paraformaldehyde, after which the platelets were permeabilized with a nonionic detergent. Analyses were performed on a Cytomics FC – 500 flow cytometer (Beckman Coulter, France), the platelet population was identified from its forward and side scatter distribution, and

5000 platelets were gated. VASP platelet reactivity index (VASP PRI) was calculated from the mean fluorescence intensity (MFI) of samples incubated with PGE<sub>1</sub> or PGE<sub>1</sub> and ADP according to the formula: VASP PRI = [(MFIc PGE1 – MFIc (PGE1 + ADP))/MFIc PGE1] × 100. According to the first VASP test patients were classified into responders or hyporesponders (VASP PRI <60% or  $\geq$ 60%, respectively) to clopidogrel.

#### 2.3. Treatment protocol

Hyporesponders received up to three additional LDs (each 600 mg), and the VASP PRI was repeated at least 12 h after each administration until a target VASP PRI (<60%) was reached. If these three additional LDs were unable to decrease the VASP PRI to <60%, patients were defined as resistant and were switched to ticagrelor. Hyporesponders received MD of 150 mg once daily for 30 days followed by MD of 75 mg till the end of 12 months in total. Responders received MD of 75 mg once daily for 12 months. Both groups were tested for VASP PRI on day 40 while on 75 mg. Hyporesponders had additional analysis of VASP PRI on day 10 while on MD of 150 mg.

#### 2.4. Genetic polymorphisms

#### 2.4.1. DNA isolation

DNA was acquired through the Latvian Genome Data Base (LGDB), a government funded biobank. DNA was extracted

from white blood cells by standard phenol-chloroform protocol, DNA concentration measured by Nanodrop ND1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA) and subsequently stored at -70 °C [23].

#### 2.4.2. SNP genotyping

DNA samples were aliquoted from storage tubes into 96-well polymerase chain reaction (PCR) plates using a Tecan with Freedom Evo system (Tecan, Mannedorf, Switzerland) disposable filter tips. DNA concentration was normalized to 7 ng/mL. Genotyping was carried out using an Applied Biosystems TaqMan SNP Genotyping Assay with a modified protocol using 4.75 mL TaqMan Genotyping Mix (Life Technologies, Carlsbad, California, USA), 0.25 mL SNP genotyping assay ID C\_25626674\_20 (Life Technologies) and 5 mL Millipore H<sub>2</sub>O (Millipore, Bedford, MA) on a Viia7 Real-Time PCR system (Life Technologies). All 7 SNPs had dbSNP identification numbers: rs4244285 (CYP2C19\*2), rs4986893 (CYP2C19\*3), rs56337013 (CYP2C19\*5), rs12248560 (CYP2C19\*17), rs1799853 (CYP2C9\*2), rs1057910 (CYP2C9\*3) and rs1045642 (ABCB1 C3435T), respectively. Probe and primer sequences are available on request. Variants were called using ViiA7 Software v1.2.1 (Life Technologies) [24].

#### 2.5. Statistical analysis

Continuous variables were compared with Student t test (for two groups) or ANOVA (for more than 2 groups). Categorical

Table 1 – Baseline demographic, clinical, angiographic and biologic characteristics ( $n = 94$ ).							
	All patients (n = 93)	Responders (n = 26)	Hyporesponders (n = 67)	Р			
Age, years	63.0 (9.7)	63.6 (10.9)	63.6 (10.9)	0.719			
Men, n (%)	49 (52.7)	13 (50.0)	36 (53.7)	0.819			
BMI, kg/m <sup>2</sup>	29.7 (4.6)	27.1 (2.8)	30.7 (4.8)	0.001			
Previous myocardial infarction, n (%)	33 (35.5)	8 (30.8)	25 (37.3)	0.554			
History of CABG, n (%)	2 (2.2)	1 (3.8)	1 (1.5)	0.647			
Cardiovascular risk factors							
Current smoker, n (%)	11 (11.8)	2 (7.7)	9 (13.6)	0.579			
Diabetes mellitus, n (%)	28 (30.1)	9 (34.6)	19 (28.4)	0.555			
Hypertension, n (%)	83 (89.2)	24 (92.3)	59 (89.4)	0.797			
Laboratory evaluation							
WBC, ×10 <sup>9</sup> /L	7.8 (2.2)	7.5 (1.5)	7.9 (2.4)	0.415			
Hemoglobin, g/L	1.4 (0.2)	1.4 (1.1)	1.4 (2.2)	0.540			
Platelets, $\times 10^{3}/L$	225.9 (51.4)	239.1 (48.8)	220.6 (51.8)	0.115			
Fibrinogen, g/L	3.4 (1.3)	3.2 (0.8)	3.4 (1.4)	0.516			
Creatinine, µmol/L	83.2 (23.9)	80.2 (16.2)	84.4 (26.3)	0.451			
GFR, mL/min	63.2 (23.9)	55.8 (15.3)	66.0 (26.0)	0.072			
TC, mmol/L	4.5 (1.4)	4.3 (1.1)	4.6 (1.4)	0.315			
HDL-C, mmol/L	1.2 (0.4)	1.3 (0.4)	1.2 (0.4)	0.654			
LDL-C, mmol/L	2.6 (1.1)	2.5 (0.9)	2.7 (1.2)	0.437			
TG, mmol/L	1.4 (0.9)	1.2 (0.7)	1.5 (1.0)	0.175			
Angiography and intervention							
Number of treated vessels	1.1 (0.2)	1.1 (0.3)	1.0 (0.2)	0.542			
Number of stents per patient	1.4 (0.6)	1.4 (0.6)	1.4 (0.6)	0.981			
Number of DES per patient	1.2 (0.4)	1.2 (0.4)	1.2 (0.5)	0.946			
GP IIb/IIIa inhibitor use, n (%)	44 (47.3)	12 (46.2)	32 (48.5)	0.840			

Values are mean (standard deviation) unless otherwise stated.

BMI, body mass index; WBC, white blood cells; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; GFR, glomerular filtration rate; DES, drug-eluting stent; GP, glycoprotein.

variables were compared with Pearson  $\chi^2$  test or Fisher exact test as appropriate. Repeated measurements were compared with paired t-test and McNemar test for continuous and categorical data, respectively. Correspondence of genotype distribution to Hardy–Weinberg equilibrium was tested with chi-square goodness of fit test. When gene dose effect was analyzed, Spearman correlation was used. Two-sided *P* value <0.05 was regarded as statistically significant. All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL).

# 3. Results

# 3.1. Patients

Baseline characteristics of the study population are summarized in Table 1. There were no differences between responders and hyporesponders regarding demographic and clinical data, except for BMI (P = 0.001; Table 1).

#### 3.2. Platelet parameters

The mean PRI after the initial dose of clopidogrel (PRI1) was  $68.4 \pm 18.9\%$ . We observed large inter-individual variability in clopidogrel responsiveness, with PRI ranging from 8% to 94% (Fig. 1). The majority of patients (n = 67, 72.0%) were hyporesponsive (PRI1  $\ge$  60%) to initial clopidogrel LD. Fig. 2A summarizes the effect of each additional clopidogrel LD on PRI in hyporesponders. The target PRI was attained with one, two and three additional LDs in 43 (66.2%), 13 (20.0%) and 9 (13.8%) patients, respectively.

Two patients (2.2%) were identified as resistant to clopidogrel as the three additional LDs were unable to achieve PRI below 60%. Both participants responded, however, to ticagrelor 180 mg (Fig. 3), which reduced PRI statistically significantly compared to PRI4 (12.0  $\pm$  1.4 vs. 73.0  $\pm$  4.2, P = 0.042).



Fig. 1 – Baseline vasodilator-stimulated phosphoprotein platelet reactivity index (PRI) after the initial loading dose of clopidogrel (n = 93).



Fig. 2 – Effect of each additional loading dose (600 mg) in hyporesponders on platelet reactivity index (PRI) (A). Effect of 150-mg and 75-mg maintenance doses at 10 and 40 days, respectively, in hyporesponders (n = 65, two resistant patients switched to ticagrelor excluded) and effect of 75-mg maintenance dose in responders (n = 26) (B).

Effect of the two MDs (150 mg and 75 mg) on PRI was investigated during follow-up on day 10 and 40, respectively, in hyporesponders, and on day 40 (75 mg MD) in responders (Fig. 2B). Only 8 (12.3%) hyporesponders had PRI  $\geq$ 60% while on 150 mg MD on day 10 compared to 32 (49.2%) patients while on 75 mg MD on day 40 (P = 0.005). On day 40, fewer patients in responders group had PRI  $\geq$ 60% (n = 2, 7.7%) compared to hyporesponders (n = 33, 50.8%) while on 75 mg MD (P < 0.001).

The mean VASP PRI for elective cases who received 300 mg LD of clopidogrel was not significantly lower compared to acute



Fig. 3 – Platelet reactivity index (PRI) in clopidogrel-resistant patients and the effect of ticagrelor.

Table 2 – Genotype distributions and allele frequencies of all investigated genetic variations.						
Polymorphism	Genotype	Patients, n (%)	P <sup>a</sup>	Allele	Allele frequency	
CYP2C19						
CYP2C19*2	GG (wt/wt)	71 (76.3)	0.686	G	0.876 (163)	
(G681A/rs4244285) <sup>b</sup>	AG (wt/*2)	21 (22.6)		А	0.124 (23)	
	AA (*2/*2)	1 (1.1)				
CYP2C19*3	GG (wt/wt)	92 (98.9)	0.958	G	0.995 (185)	
(G636A/rs4986893)	AG (wt/*3)	1 (1.1)		А	0.005 (1)	
CYP2C19*5	CC (wt/wt)	90 (100.0)	NA	С	1.000 (90)	
(C1297T/rs56337013)	CT (wt/*5)					
CYP2C19*17	CC (wt/wt)	36 (38.7)	0.523	С	0.634 (118)	
(C806T/rs12248560)	CT (wt/*17)	46 (49.5)		Т	0.366 (68)	
	TT (*17/*17)	11 (11.8)				
CYP2C9						
CYP2C9*2	CC (wt/wt)	86 (92.5)	0.706	С	0.962 (179)	
(C430T/rs1799853)	CT (wt/*2)	7 (7.5)		Т	0.038 (7)	
CYP2C9*3	AA (wt/wt)	79 (84.9)	0.433	А	0.925 (172)	
(A1075C/rs1057910)	CA (wt/*3)	14 (15.1)		С	0.075 (14)	
ABCB1						
ABCB1	CC	17 (18.2)	0.410	С	0.452 (84)	
(C3435T/rs1045642)	CT	50 (53.8)		Т	0.548 (102)	
	TT	26 (28.0)				
NA, not applicable; wt, wild-type; SNP, single-nucleotide polymorphism.						

<sup>a</sup> Hardy–Weinberg equilibrium.

<sup>b</sup> According to National Center for Biotechnology Information.

patients who received 600 mg LD of clopidogrel (67.2  $\pm$  19.7 vs. 74.0  $\pm$  8.0, P = 0.285).

#### 3.3. Genotyping results

No deviations from the Hardy–Weinberg equilibrium were detected. Genotype distribution and allele frequencies of the genetic variations studied are presented in Table 2. For the CYP2C19 genotype, one patient was homozygote for the \*2 mutant allele of CYP2C19 (1.1%), 21 (22.6%) were heterozygotes and 71 (76.3%) were homozygotes for the wild-type allele.

#### 3.4. Relationship of genotypes with PRI

Table 3 summarizes platelet reactivity after the first routine dose (PRI1) by genotypes. Carriers of the CYP2C19\*2 allele (wt/\*2 and \*2/\*2) had significantly higher PRI1 compared with patients homozygous for CYP2C19 wild-type genotype (78.2  $\pm$  13.1 vs. 65.3  $\pm$  19.5, P = 0.005).

Platelet activity remained higher in carriers of the CYP2C19\*2 allele (wt/\*2 and \*2/\*2) after the first additional LD (PRI2) compared with homozygotes of CYP2C19 wild-type genotype (57.0  $\pm$  19.1 vs. 40.8  $\pm$  21.5, P = 0.006) (Fig. 4). The absolute decrease of mean PRI following the first additional LD (PRI1–PRI2) was significantly smaller in carriers vs. noncarriers of \*2 (25.2  $\pm$  15.6 vs. 35.5  $\pm$  16.8, P = 0.025) (Table 4).

The platelet reactivity with two different MDs of clopidogrel in the whole group and responders/non-responders stratified by the genotypes is summarized in Table 5. Both MDs were less effective in the presence of CYP2C19\*2. Among hyporesponders, carriers of CYP2C19\*2 (wt/\*2 and \*2/\*2) had significantly higher PRI on day 10 while on the 150 mg MD ( $53.3 \pm 12.1$  vs.  $40.3 \pm 13.5$ , P = 0.001) and on day 40 while on the 75 mg MD ( $65.5 \pm 10.4$  vs.  $56.3 \pm 14.5$ , P = 0.020) compared with homozygous for CYP2C19 wild type genotype. In the whole study group carriers of CYP2C19 \*2 had higher PRI with 75 mg MD (63.1  $\pm$  11.3 vs. 50.3  $\pm$  17.1, P = 0.002).

Target PRI <60% was achieved in 70.6% vs. 93.8% of patients with 150 mg MD (P = 0.024), and 23.5% vs. 58.3% with 75 mg MD (P = 0.014) in carriers and non-carriers, respectively. The success

Table 3 - Repartition of genetic polymorphisms of

CVD2C0 am

the initial dose of clopidogrel ( $n = 93$ ).					
Variable	PRI1, % (SD)	Р	Hyporesponders (n = 67)	Р	
CYP2C19*2 wt/wt wt/*2 *2/*2	65.3 (19.5) 77.7 (13.2) 89.0 (–)	0.016	48/71 (67.6) 18/21 (85.7) 1/1 (100)	0.220	
CYP2C19*3 wt/wt wt/*3	68.2 (19.0) 82.0 (–)	0.472	66/92 (71.7) 1/1 (100)	1.000	
CYP2C19*17 wt/wt wt/*17 *17/*17	73.0 (15.0) 64.7 (20.7) 68.7 (20.8)	0.140	29/36 (80.6) 30/46 (65.2) 8/11 (72.7)	0.307	
CYP2C9*2 wt/wt wt/*2	68.6 (18.9) 65.6 (20.6)	0.687	63/86 (73.3) 4/7 (57.1)	0.361	
CYP2C9*3 wt/wt wt/*3	69.1 (17.7) 64.3 (25.2)	0.385	58/79 (73.4) 9/14 (64.3)	0.488	
ABCB1 CC CT TT	67.0 (22.5) 66.5 (18.7) 72.8 (16.9)	0.379	11/17 (64.7) 36/50 (72.0) 20/26 (76.9)	0.683	



Fig. 4 – Platelet reactivity after clopidogrel each loading dose depending on genetic polymorphism of CYP2C19\*2 (n = 93).

rate was statistically significantly improved with higher MD both in carriers and non-carriers of CYP2C19<sup>\*</sup>2 (P = 0.008 and P < 0.001, respectively).

Patients with CYP2C19\*17 allele (wt/\*17 and \*17/\*17) had lower PRI1 compared with homozygous for CYP2C19 wild-type genotype ( $65.4 \pm 20.6$  vs.  $73.0 \pm 15.0$ , P = 0.060) (Table 3). Carriers of both gain-of-function allele of the CYP2C19\*17 (\*17/\*17) had similar PRI1 compared with patients with one gain-of-function allele or homozygotes of the wild-type allele (wt/\*17 and wt/wt) ( $68.3 \pm 18.8$  vs.  $68.7 \pm 20.8$ , P = 0.947). No other polymorphism in recessive or dominant model had significant association with baseline or any other PRI.

The two clopidogrel-resistant patients had the following genotypes: (i) patient A, CYP2C9\*3 wt/wt, CYP2C9\*2 wt/wt, CYP2C19\*2 wt/\*2, CYP2C19\*3 wt/wt, CYP2C19\*5 wt/wt, CYP2C19\*17 wt/\*17, ABCB1 C/T, and (ii) patient B, CYP2C9\* 3wt/wt, CYP2C9\*2 wt/wt, CYP2C19\*2 wt/\*2, CYP2C19\*3 wt/wt, CYP2C19\*5 wt/wt, CYP2C19\*17 wt/wt, ABCB1 T/T.

Table 4 – Influence of the first additional loading dose of clopidogrel on the platelet reactivity according to the CYP2C19, CYP2C9 and ABCB1 genotypes.					
Genotype	n	PRI1–PRI2, % (SD)	Р		
CYP2C19*2					
wt/wt	48	35.5 (16.8)	0.025		
wt/*2 and *2/*2	19	25.2 (15.6)			
CYP2C19*17					
wt/wt	29	31.7 (16.2)	0.705		
wt/*17 and *17/*17	38	33.3 (17.8)			
CYP2C19*3					
wt/wt	66	32.8 (17.1)	0.392		
wt/*3	1	18.0 (-)			
CYP2C9*2					
wt/wt	63	32.3 (17.1)	0.659		
wt/*2	4	36.3 (17.4)			
CYP2C9*3					
wt/wt	58	32.9 (17.5)	0.691		
wt/*3	9	30.4 (14.3)			
ABCB1					
CC	17	32.9 (17.1)	0.719		
CT/TT	76	30.8 (17.3)			

# 4. Discussion

Our study confirms the previous reports that the patients carrying the loss-of-function CYP2C19\*2 allele have significantly higher PRI following an initial LD of clopidogrel than wild-type homozygotes [2]. In addition, we have demonstrated that PRI reduction (PRI1–PRI2) after the first additional 600 mg LD of clopidogrel is significantly smaller in CYP2C19\*2 allele carriers. Similar trend was observed after the second and subsequent loading doses, which was non-significant presumably due to smaller number of patients requiring more than one additional LD.

Previous studies reporting on the impact of ABCB1 C3435T genotypes on clopidogrel treatment efficacy have provided inconsistent results. For instance, in the PLATO trial the ABCB1 3435CC high-expression genotype was associated with increased risk of cardiovascular death, myocardial infarction, and stroke in the clopidogrel arm of the study [17], whereas in the TRITON-TIMI 38 trial, the highest event rates were observed in carriers of the opposite (3435TT) ABCB1 genotype [25]. Importantly, in a meta-analysis by Su et al. T allele was associated with increased early and long-term risk of major cardiovascular events with 300 mg LD, but not with 600 mg LD [26]. Our data go in line with this analysis as we observed similar, although nonsignificant, trend of higher PRI values with TT genotype after the initial LD.

Of note, in none of the studies included in the metaanalysis dose adjustment guided by platelet function testing was performed. Such study, however, has been recently published by Bonello et al. [18], in which they found that CYP2C19\*2, but neither PON1 nor ABCB1 genotype, was associated with HTPR after the initial LD, while only ABCB1 was responsible for the failure of the additional LD strategy. Since there were only two patients in whom dose-adjustment failed in our study, the statistical comparison with the other patients was not feasible. Both clopidogrel-resistant patients, however, were carriers of T allele (heterozygote and homozygote), as well as heterozygotes for CYP2C19\*2, which supports the notion that both alleles may be involved in resistance, but not the only responsible factors. Importantly, both patients had pronounced response to ticagrelor, underscoring the advantage of the newer drug.

There are several differences between our study and the study reported by Bonello et al. [18]. In our study the sample was smaller, most of patients underwent scheduled PCI and thus received 300 mg initial LD in line with the current guidelines [1], as well as the target PRI was <60%. In contrast, Bonello et al. included only patients with acute coronary syndrome receiving 600 mg of initial LD, and set the target PRI <50%. Importantly, first blood sample for VASP analysis was taken after the PCI in our study as opposed to before the intervention in the study by Bonello et al. One may argue that mechanical injury itself may augment platelet reactivity and confound the findings. It remains unclear, however, to what extent, if any, the different findings regarding effects of ABCB1 C3435T can be attributed to the above-mentioned factors. Altogether our data suggest, that CYP2C19\*2 has much stronger impact on PRI reduction with additional LD than ABCB1 T allele.

Table 5 – Inf polymorphis	luence of the	e two maintenance do	oses of clopic	logrel on the platele	et reactivity accord	ling to the genetic
Variable	n	Responders (n = 26)	n	Hyporespond	ders (n = 65) <sup>a</sup>	All patients $(n = 91)^a$
		75 mg		150 mg	75 mg	75 mg

		75 mg		150 mg	75 mg	75 mg
CYP2C19*2						
wt/wt	23	37.7 (15.4)	48	40.3 (13.5)	$\textbf{56.3} \pm \textbf{14.5}$	50.3 (17.1)
wt/*2	3	49.7 (5.1)	16	51.9 (10.9)	$64.7\pm10.2$	62.3 (11.0)
*2/*2	-		1	76.0 (–)	78.0 (–)	78.0 (–)
		P = 0.198		P = 0.001	P = 0.043	P = 0.006
CYP2C19*3						
wt/wt	21	38.8 (15.0)	56	43.1 (14.6)	59.5 (13.7)	52.8 (16.6)
wt/*3	5	40.0 (16.9)	9	47.8 (11.8)	53.7 (15.8)	81.0 (-)
		P = 0.877		P = 0.362	P = 0.247	P = 0.095
CYP2C19*17						
wt/wt	7	32.1 (8.0)	28	45.5 (15.1)	58.7 (11.8)	3.4 (15.4)
wt/*17	16	41.6 (17.7)	29	42.1 (14.6)	59.0 (16.2)	52.8 (18.6)
*17/*17	3	41.7 (7.5)	8	43.3 (9.7)	57.9 (14.3)	53.5 (14.6)
		P = 0.379		P = 0.665	P = 0.982	P = 0.984
CYP2C9*2						
wt/wt	23	39.8 (15.8)	61	43.8 (13.8)	59.0 (14.3)	53.7 (17.0)
wt/*2	3	33.3 (2.5)	4	42.0 (23.0)	55.0 (9.6)	45.7 (13.5)
		P = 0.495		P = 0.805	<i>P</i> = 0.588	P = 0.228
CYP2C9*3						
wt/wt	21	38.8 (15.0)	56	43.1 (14.6)	59.5 (13.7)	53.9 (16.8)
wt/*3	5	40.0 (16.9)	9	47.8 (11.8)	53.7 (15.8)	48.8 (17.0)
		P = 0.877		P = 0.362	P = 0.247	P = 0.299
ABCB1						
C/C	6	49.5 (18.3)	11	45.6 (12.0)	62.1 (13.6)	57.7 (16.1)
C/T	6	34.2 (12.0)	35	42.1 (15.1)	58.1 (14.0)	51.3 (17.2)
T/T	14	39.8 (14.9)	19	46.2 (14.2)	57.9 (14.8)	53.6 (16.5)
		P = 0.109		P = 0.595	P = 0.688	P = 0.404
<sup>a</sup> Two clopidogr	el-resistant p	atients switched to tica	agrelor were exc	luded.		

In our view there is a discrepancy between the high prevalence of patients not reaching target PRI <50% reported in literature (from 16% to 50%) and much lower frequency of stent thrombosis rates observed in the randomized studies during the first year (<1%) [9,27,28]. We therefore attempted to test the safety of PRI <60% as a less conservative target for the dose-adjustment strategy. The one-year clinical follow-up data will be reported separately.

Despite the raised cut-off value, the prevalence of hyporesponders with PRI ≥60% after the initial LD was higher than expected (72.0%). One may speculate that DES is more frequently chosen in diabetics and complicated lesions, hence higher atherosclerosis burden, which in turn may be associated with higher platelet reactivity and lead to a selection bias. Use of 300 mg LD may be another factor contributing to higher PRI, although in our sample elective cases receiving 300 mg LD had lower PRI than acute patients receiving 600 mg LD.

We observed that CYP2C19\*2 carriers had higher PRI with both 75 mg MD and 150 mg MD of clopidogrel. In these patients 150 mg MD was significantly more effective than 75 mg MD to maintain target PRI <60%. We did not find significant interaction of ABCB1 genotype and efficacy of either MD. These findings confirm previous reports [10,29,30] that 150 mg MD may be preferred to 75 mg in carriers of CYP2C19\*2, although no benefit of such strategy has been shown to improve clinical outcomes. In our view this finding additionally supports importance of CYP2C19\*2 over ABCB1 since effect of LD is short-lasting.

No other polymorphisms (CYP2C19\*3, CYP2C19\*5, CYP2C 19\*17, CYP2C9\*2, CYP2C9\*3 and ABCB1 C3435T) were found to have clearly significant interaction with LDs or MDs. It should be noted, that minor alleles of these polymorphisms are rare, and therefore are unlikely to have as high clinical significance as CYP2C19\*2 if the type 2 statistical error was present. Besides the smaller sample size, another limitation of the study is the heterogeneity of study group as about one fifth of the patients had ACS and received 600 mg initial LD.

The advantage of the present study is the use of the platelet VASP test (PLT-VASP), which is highly specific to P2Y<sub>12</sub> inhibition. This method has other significant logistical advantages including: (i) aspirin and other medications such as GPIIb/IIIa antagonists do not interfere with the results, (ii) analysis can be performed within 48 h from the collection of the blood, (iii) the samples can be stored at room temperature, (iv) only a single full citrate tube is required.

The results of the present study are of potential interest to help define a therapeutic strategy to improve platelet reactivity inhibition in hyporesponders. Integrated approach of testing both presence of CYP2C19\*2 and degree of platelet reactivity may be superior to platelet function testing alone in order to achieve the most optimal P2Y12 inhibition in each individual patient.

# 5. Conclusions

In patients hyporesponsive to a routine clopidogrel doses the potency of additional LD and higher MD of clopidogrel is compromised by presence of CYP2C19\*2 allele. The doseadjustment strategy is not affected by ABCB1 C3435T or CYP2C9 genotypes.

# **Conflict of interest statement**

The authors state no conflict of interest.

# Acknowledgments

Financial support of European Social Fund project "Support for doctoral students in acquiring study program and acquisition of the scientific degree in Riga Stradins University" (No. 2009/ 0147/1DP/1.1.2.1.2/09/IPIA/VIAA/009). Work was supported by European Regional Development Fund Project (2010/0311/2DP/ 2.1.1.1.0/10/APIA/VIAA/069). We acknowledge Genome Database of Latvian Population, Latvian Biomedical Research and Study Centre for providing genetic data and DNA samples.

#### REFERENCES

- Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501–55.
- [2] Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–33.
- [3] King III SB, Smith Jr SC, Hirshfeld Jr JW, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117:261–95.
- [4] Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353–63.
- [5] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.
- [6] Angiolillo DJ, Fernandez-Orliz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel. Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505–16.

- [7] Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945–54.
- [8] Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404–11.
- [9] Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5–10.
- [10] Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097–105.
- [11] Wang XD, Zhang DF, Zhuang SW, Lai Y. Modifying clopidogrel maintenance doses according to vasodilatorstimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol 2011;34:332–8.
- [12] Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Konyi A, et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest 2012;42:384–92.
- [13] Ari H, Ozkan H, Karacinar A, Ari S, Koca V, Bozat T. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012;157:374–80.
- [14] Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012;59:2159–64.
- [15] Aradi D, Komocsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 2012;167:2140–8.
- [16] Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–75.
- [17] Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320–8.
- [18] Bonello L, Camoin-Jau L, Mancini J, Bessereau J, Grosdidier C, Alessi MC, et al. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thromb Res 2012;130:70–4.
- [19] Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart

Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645–81.

- [20] Taggart DP, Boyle R, de Belder MA, Fox KA. The 2010 ESC/ EACTS guidelines on myocardial revascularisation. Heart 2011;97:445–6.
- [21] Taylor J. 2012 ESC guidelines on acute myocardial infarction (STEMI). Eur Heart J 2012;33:2501–2.
- [22] Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85–92.
- [23] Ciganoka D, Balcere I, Kapa I, Peculis R, Valtere A, Nikitina-Zake L, et al. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. Eur J Endocrinol 2011;165:517–25.
- [24] Peculis R, Latkovskis G, Tarasova L, Pirags V, Erglis A, Klovins J. A nonsynonymous variant I248L of the adenosine A3 receptor is associated with coronary heart disease in a Latvian population. DNA Cell Biol 2011;30:907–11.
- [25] Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312–9.

- [26] Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 2012;7:e46366.
- [27] Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost 2012;107:494–506.
- [28] Sudhir K, Hermiller JB, Ferguson JM, Simonton CA. Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol 2013;2013:748736.
- [29] Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012;59: 1928–37.
- [30] Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008;1:631–8.